

New Frontiers in Anti-Atherosclerotic Therapies

SAVE THE DATE

March 13, 2010

The Georgia World Congress Center – Atlanta, Georgia

www.ccfcmc.org/Frontier10



New Frontiers in Anti-Atherosclerotic Therapies

Description

This course will review new therapeutic targets for atherosclerotic cardiovascular disease.

Course Objectives

- Classify benefit of targeting risk factors
- Distinguish degree of residual risk despite risk factor modification
- Review novel therapeutic strategies

Target Audience

- Physicians and Nursing staff involved in prevention of cardiovascular disease

Faculty Disclosure

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 3.5 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Americans with Disabilities Act

The Cleveland Clinic Foundation Center for Continuing Education fully intends to comply with the legal requirements of the Americans with Disabilities Act. If you need assistance, please notify Jamie Belkin at 216.932.3448 at least two weeks prior to the activity.

Course Director

Stephen Nicholls, MBBS, PhD
Cleveland Clinic
Cleveland, OH

Course Co-Chair

Steven Nissen, MD
Cleveland Clinic
Cleveland, OH

Guest Faculty

Christie Ballantyne, MD
Baylor College of Medicine
Houston, TX

Philip Barter, MD, PhD

The Heart Research Institute
Sydney, Australia

Bryan Brewer, MD

MedStar Research Institute
Washington, DC

Alan Daugherty, PhD

University of Kentucky
Lexington, KY

Michael Davidson, MD

University of Chicago
Chicago, IL

John Kastelein, MD, PhD

University of Amsterdam
Amsterdam, The Netherlands

Agenda **Saturday, March 13, 2010**

Chairs:	Steven Nissen, MD Stephen Nicholls, MBBS, PhD
7:00-8:00AM	Continental Breakfast
8:00-8:10AM	Welcome Stephen Nicholls, MBBS, PhD
8:10-8:35AM	Atherosclerosis Imaging: What Have We Learned? Steven Nissen, MD
8:35-9:00AM	LDL: How Low Should We Go? Michael Davidson, MD
9:00-9:25AM	CETP Inhibition: Will It Work? Philip Barter, MD, PhD
9:25-9:50AM	Infusion of HDL Mimetics Bryan Brewer, MD
9:50-10:15AM	Break
10:15-10:40AM	Induction of APOA-I Synthesis John Kastelein, MD, PhD
10:40-11:05AM	LP-PLA2 Inhibition Christie Ballantyne, MD
11:05-11:30AM	Renin Inhibition as an Anti-Atherosclerotic Strategy Alan Daugherty, MD
11:30- 11:55AM	Slowing Disease Progression: What Does It Mean? Stephen Nicholls, MBBS, PhD
11:55AM	Wrap-Up Steven Nissen, MD

Time for questions and answers will be included in each presentation.

Location: Georgia World Congress Center – Room B308

Course 020633

Registration: Please go to www.clevelandclinic.org/Frontier10 to register for this course

For further information about this course, please contact Jamie Belkin at 216.932.3448 or jamie@jamiebelkin.com



The Cleveland Clinic Foundation
9500 Euclid Avenue / JJ65
Cleveland, OH 44195



New Frontiers in Anti-Atherosclerotic Therapies

March 13, 2010

The Georgia World Congress Center
Atlanta, Georgia

www.ccfme.org/Frontier10

This event is not part of the official ACC Annual Scientific Session and/or the ACC's Innovation in Intervention: i2 Summit in Partnership with the Cardiovascular Research Foundation, as planned by their Program Committees.